Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 17/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.57 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139791 | 1.00 | APP (0.64) | APPMAPTSULT1A1SNCAMEN1 | |
| SCHEMBL4152928 | 1.00 | APP (0.64) | APPMAPTSULT1A1SNCAMEN1 | |
| SCHEMBL4008927 | 0.91 | APP (0.64) | APPMAPTSULT1A1SNCA | |
| SCHEMBL4162869 | 0.91 | APP (0.64) | APPMAPTSULT1A1SNCA | |
| SCHEMBL4162128 | 0.91 | APP (0.64) | APPMAPTSULT1A1SNCA | |
| SCHEMBL4154609 | 0.91 | APP (0.64) | APPMAPTSULT1A1SNCA | |
| SCHEMBL24133662 | 0.89 | APP (0.64) | APPMAPTSULT1A1SNCAMEN1 | |
| SCHEMBL30482941 | 0.89 | APP (0.64) | APPMAPTSULT1A1SNCAMEN1 | |
| SCHEMBL21751814 | 0.88 | APP (0.59) | APPMAPTSULT1A1SNCAMEN1 | |
| SCHEMBL12808066 | 0.86 | APP (0.70) | APPMAPTSULT1A1SNCAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893245-A4 | RADIOLABELED-PEGYLATION OF LIGANDS FOR USE AS IMAGING AGENTS | UNIV PENNSYLVANIA (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1893245-A2 | RADIOLABELED-PEGYLATION OF LIGANDS FOR USE AS IMAGING AGENTS | The Trustees of the University of Pennsylvania (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070031328-A1 | Radiolabeled-pegylation of ligands for use as imaging agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-08 | — | — | US | disclosed |
| WO-2007002540-A2 | RADIOLABELED-PEGYLATION OF LIGANDS FOR USE AS IMAGING AGENTS | KUNG HANK F (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070031328-A1 | Radiolabeled-pegylation of ligands for use as imaging agents | EGFR, LANCL1, FLT1 | APP 4458/4885MAPT 2692/4885SULT1A1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.